MaxCyte, Inc. 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023, filed March 12, 2024. The filing is an annual report; it does not provide a clear standalone fourth-quarter 2023 income statement or cash flow statement.
Business Context
MaxCyte provides Flow Electroporation-based cell engineering technologies for cell therapy, gene editing, immuno-oncology, drug and biologic discovery, and biomanufacturing. Its ExPERT platform includes ATx, STx, GTx and VLx instruments, processing assemblies, buffers and related licenses.
- Installed base increased to 683 instruments from 616 at year-end 2022.
- The company had 26 strategic platform license partnerships, 23 active SPLs, more than 160 licensed clinical programs, 16 programs in clinical development and one commercial program.
- Potential precommercial milestone payments under SPLs exceeded $1.95 billion, but these amounts are contingent on partner development and regulatory success and are not forecast revenue.
- MaxCyte had 143 full-time employees at year-end, compared with 125 at year-end 2022.
Financial Performance and Liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Total revenue | $41.3 million | $44.3 million | Down 7% |
| Core revenue | $29.8 million | $39.6 million | Down 25% |
| Program-related revenue | $11.5 million | $4.6 million | Up 148% |
| Gross profit | $36.5 million | $39.2 million | Down 7% |
| Gross margin | 89% | 88% | Up 1 percentage point |
| Operating loss | $48.3 million | $27.4 million | Loss increased |
| Net loss | $37.9 million | $23.6 million | Loss increased |
| Basic and diluted loss per share | $0.37 | $0.23 | Loss per share increased |
| Cash flow from operations | $(21.7) million | $(14.8) million | Use increased |
- Core revenue declined primarily because instrument revenue fell 29% to $8.3 million and disposables revenue fell 36% to $10.3 million. Lease revenue declined 5% to $10.3 million.
- Program-related revenue increased due to clinical and regulatory milestones, highlighting the variability of milestone-driven revenue.
- Research and development expense rose 22% to $23.8 million; sales and marketing rose 45% to $27.0 million; general and administrative expense rose 16% to $30.1 million.
- Interest and other income increased to $10.4 million from $3.9 million, primarily due to higher interest rates and a larger average investment balance.
- Cash, cash equivalents and short- and long-term investments totaled $211.2 million at December 31, 2023, including $46.5 million of cash and cash equivalents and $164.7 million of investments.
- Net cash increased by $35.4 million, largely because investment maturities exceeded purchases; operating activities consumed $21.7 million.
- The company had no debt obligations at year-end. Operating lease liabilities totaled $18.7 million, with approximately $29.6 million of incremental non-cancellable lease payments through the lease term ending August 31, 2035.
- Accumulated deficit was $175.8 million, and U.S. federal and state net operating loss carryforwards totaled approximately $88.9 million.
Material Changes Versus 2022
- Revenue decreased despite substantially higher program-related milestone revenue, as core product revenue weakened across cell therapy and drug discovery markets.
- Operating losses widened as the company invested in research and development, commercial infrastructure, manufacturing scale-up and public-company operations.
- Gross margin improved modestly because milestone revenue carries little or no cost of goods sold, partly offset by initial in-house processing assembly scale-up costs and a $0.7 million inventory reserve.
- Inventory increased to $12.2 million from $8.6 million, including a $0.7 million excess and obsolete inventory reserve.
- Stock-based compensation increased to $14.0 million from $11.8 million and diluted the share base through equity awards and exercises.
- Chief Executive Officer Maher Masoud replaced Doug Doerfler in December 2023, creating management-transition risk.
Outlook, Commentary and Risks
Management expects continued operating losses while it expands sales and marketing, research and development, manufacturing capacity and product offerings. Management stated that existing cash, investments and internally generated cash flows are expected to fund operating expenses and capital expenditures for at least the next 12 months, but this assessment depends on assumptions that may prove incorrect.
- Program-related revenue is expected to remain volatile because it depends on partner clinical, regulatory and commercial milestones outside MaxCyte’s control.
- Two SPL customers represented 39% of 2023 revenue, and the five largest customers represented approximately 52%, creating significant customer-concentration risk.
- One customer represented 30% of 2023 revenue; three customers represented 38% of accounts receivable at year-end.
- Approximately 56% of inventory purchases in 2023 came from one supplier, and certain components are sourced from single or limited suppliers.
- Key risks include customer funding constraints, clinical or regulatory failures at partners, termination of partnerships, competition, product adoption, manufacturing execution, inventory forecasting, cybersecurity, data privacy, international operations, intellectual property and the need for additional capital.
- The company has not received commercial sales-based payments from SPL customers to date, and the filing does not provide a clear forecast for when such payments may begin.
- The company reported no material cybersecurity incident to date and no material legal proceedings. Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2023; the external auditor did not provide an internal-control attestation because of the company’s emerging growth company status.
Important Facts for Investors to Verify
- Whether core revenue stabilizes or recovers after the 2023 decline in instrument and disposable sales.
- The sustainability, timing and concentration of SPL milestone revenue, and the probability of converting the stated $1.95 billion potential milestone pool into actual cash receipts.
- Progress of the 16 clinical programs and the one commercial program, including regulatory approvals and potential commercial sales-based payments.
- Cash burn, investment balances and the duration of liquidity in light of continuing losses and planned spending increases.
- Execution of the VLx and in-house processing assembly manufacturing strategy, including demand, capacity, quality and inventory risks.
- Customer and supplier concentration, particularly the dependence on major SPL partners and the supplier representing approximately 56% of 2023 inventory purchases.
- Impact of the December 2023 CEO transition on strategy, employee retention, partnerships and operating performance.
- Potential dilution from outstanding equity awards; approximately 15.4 million stock options and 1.3 million restricted stock units were outstanding at year-end 2023.